It was suggested that SV therapy could be a therapeutic plan for reducing the number of ventricular arrhythmias through three different pathways, including B‐type natriuretic peptide, angiotensin II, and bradykinin. The gene discussed is KNG1; the disease is Ventricular arrhythmia.